The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis
Abstract
Constitutive activation of the NF-κB has been documented to be involved in the pathogenesis of many human malignancies, including hemopoietic neoplasms. In this study, we examined the status of NF-κB in two non-Hodgkin’s lymphoma cell lines derived from mantle cell lymphoma (MCL) samples and in patient MCL biopsy specimens by EMSA and confocal microscopic analysis. We observed that NF-κB is constitutively activated in both the MCL cell lines and in the MCL patient biopsy cells. Since NF-κB has been shown to play an important role in a variety of cellular processes, including cell cycle regulation and apoptosis, targeting the NF-κB pathways for therapy may represent a rational approach in this malignancy. In the MCL cell lines, inhibition of constitutive NF-κB by the proteasome inhibitor PS-341 or a specific pIκBα inhibitor, BAY 11-7082, led to cell cycle arrest in G1 and rapid induction of apoptosis. Apoptosis was associated with the down-regulation of bcl-2 family members bcl-xL and bfl/A1, and the activation of caspase 3, that mediates bcl-2 cleavage, resulting in the release of cytochrome c from the mitochondria. PS-341or BAY 11-induced G1 cell cycle arrest was associated with the inhibition of cyclin D1 expression, a molecular genetic marker of MCL. These studies suggest that constitutive NF-κB expression plays a key role in the growth and survival of MCL cells, and that PS-341 and BAY 11 may be useful therapeutic agents for MCL, a lymphoma that is refractory to most current chemotherapy regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194
Conversion of Bcl-2 to a Bax-like Death Effector by Caspases
Cheng, E. H.-Y., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., Ueno, K., & Hardwick, J. M. (1997) · Science · doi:10.1126/science.278.5345.1966 · Cited by 1,107
Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., & Gerritsen, M. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21096 · Cited by 1,053
Constitutive Activation of NF-κB during Progression of Breast Cancer to Hormone-Independent Growth
Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., & Sledge, G. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3629 · Cited by 819
Hinz, M., Krappmann, D., Eichten, A., Heder, A., Scheidereit, C., & Strauss, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2690 · Cited by 788
Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119849 · Cited by 761
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L., Cleary, K. R., & Chiao, P. J. (1999) · PubMed · Cited by 651
Wang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 590
Lee, H. H., Dadgostar, H., Cheng, Q., Shu, J., & Cheng, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9136 · Cited by 521
NF-κB Activation: The IκB Kinase Revealed?
Stancovski, I., & Baltimore, D. (1997) · Cell · doi:10.1016/s0092-8674(00)80413-4 · Cited by 492
Activation of the cell death program by inhibition of proteasome function
Drexler, H. C. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.855 · Cited by 481
Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N. T., Bancroft, C. C., Sausville, E. A., Adams, J., Elliott, P. J., & Waes, C. V. (2001) · PubMed · Cited by 473
The proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 472
The Ubiquitin-Proteasome Pathway and Pathogenesis of Human Diseases
Schwartz, P., & Ciechanover, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.57 · Cited by 466
Shimizu, S., Konishi, A., Kodama, T., & Tsujimoto, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3100 · Cited by 433
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Grumont, R. J., Rourke, I. J., & Gerondakis, S. (1999) · Genes & Development · doi:10.1101/gad.13.4.400 · Cited by 403
Cytochrome c release from mitochondria: all or nothing
Martinou, J.-C., Desagher, S., & Antonsson, B. (2000) · Nature Cell Biology · doi:10.1038/35004069 · Cited by 318
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
Russo, S. M., Tepper, J. E., Baldwin, A. S., Liu, R., Adams, J., Elliott, P., & Cusack, J. C. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01446-8 · Cited by 318
Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells
Keller, S. A., Schattner, E. J., & Cesarman, E. (2000) · Blood · doi:10.1182/blood.v96.7.2537 · Cited by 315
Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells.
Mori, N., Fujii, M., Ikeda, S., Yamada, Y., Tomonaga, M., Ballard, D. W., & Yamamoto, N. (1999) · PubMed · doi:10.1182/blood.v93.7.2360 · Cited by 285
NF-κB inhibition causes spontaneous apoptosis in Epstein–Barr virus-transformed lymphoblastoid cells
Cahir-McFarland, E. D., Davidson, D. M., Schauer, S. L., Duong, J., & Kieff, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100119497 · Cited by 259
Chiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., et al. (2000) · Blood · doi:10.1182/blood.v95.2.619 · Cited by 216
Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome
Bold, R. J., Virudachalam, S., & McConkey, D. J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6194 · Cited by 212
Frankel, A., Man, S., Elliott, P. J., Adams, J., & Kerbel, R. S. (2000) · PubMed · Cited by 201
Li, J. J., Westergaard, C. K., Ghosh, P., & Colburn, N. H. (1997) · PubMed · Cited by 199
Survival of leukemic B cells promoted by engagement of the antigen receptor
Bernal, A., Pastore, R. D., Asgary, Z., Keller, S. A., Cesarman, E., Liou, H.-C., & Schattner, E. J. (2001) · Blood · doi:10.1182/blood.v98.10.3050 · Cited by 195
Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes
Ho, A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00263-5 · Cited by 192
Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation
Medeiros, L. J., van Krieken, J., Jaffe, E., & Raffeld, M. A. (1990) · Blood · doi:10.1182/blood.v76.10.2086.2086 · Cited by 191
The DNA repair protein Rad23 is a negative regulator of multi-ubiquitin chain assembly
Ortolan, T. G., Tongaonkar, P., Lambertson, D., Chen, L., Schauber, C., & Madura, K. (2000) · Nature Cell Biology · doi:10.1038/35023547 · Cited by 186
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., Terry, N. H. A., Reid, P. S., & Ford, R. J. (2002) · Immunity · doi:10.1016/s1074-7613(01)00258-8 · Cited by 127
Self-citationThe role of nuclear factor-?b in the biology and treatment of multiple myeloma
Berenson, J. R., Ma, H. M., & Vescio, R. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90036-3 · Cited by 124
Chaturvedi, M., LaPushin, R., & Aggarwal, B. B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36662-0 · Cited by 120
Swerdlow, S., Yang, W. J., Zukerberg, L. R., et al. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90090-x · Cited by 103
Naujokat, C., Sezer, O., Zinke, H., Leclere, A., Hauptmann, S., & Possinger, K. (2000) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2000.065004221.x · Cited by 89
New agents in cancer clinical trials
Adams, J., & Elliott, P. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204088 · Cited by 80
Zhang, X., Lin, H., Chen, C., & Chen, B. D. ‐. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3400127 · Cited by 79
Proteasome inhibitors as anti-cancer agents
Murray, R. Z., & Norbury, C. J. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200007000-00001 · Cited by 57
Establishment and characterization of a new mantle cell lymphoma cell line, Mino
Lai, R., McDonnell, T. J., O’Connor, S. L., Medeiros, L. J., Oudat, R., Keating, M. J., Morgan, M. B., Curiel, T. J., & Ford, R. J. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00013-9 · Cited by 53
Self-citationCyclin D1 over expression in malignant lymphomas
Nakamura, S., Yatabe, Y., & Seto, M. (1997) · Pathology International · doi:10.1111/j.1440-1827.1997.tb04519.x · Cited by 52
The emerging epidemic of non-Hodgkin's lymphoma: current knowledge regarding etiological factors.
Levine, P. H., & Hoover, R. N. (1992) · PubMed · Cited by 39
Sundaresan, A., Claypool, K., Mehta, K., Lopez‐Berestein, G., Cabanillas, F., & Ford, R. J. (1997) · PubMed · Cited by 32
Self-citationCONSTITUTIVE ACTIVATION OF NF- κ B IN PRIMARY ADULT T-CELL LEUKEMIA CELLS
Mori, N., Fujii, M., Ikeda, S., Yamada, Y., Tomonaga, M., Ballard, D. W., & Yamamoto, N. (1999) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199904010-00027 · Cited by 8
Cited by
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.050 · Cited by 577
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Pérez-Galán, P., Roué, G., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2006) · Blood · doi:10.1182/blood-2005-05-2091 · Cited by 467
Metadata
- Authors
- Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-07-01
- Volume
- 171
- Issue
- 1
- Pages
- 88-95
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2116090592
- Cited by
- 320
- References
- 51
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.